KRT19

(redirected from CK19)

KRT19

A gene on chromosome 17q21.2 that encodes the smallest of all type-I keratin proteins, which is expressed in the periderm, the transiently superficial layer that surrounds the developing epidermis.
References in periodicals archive ?
3 Immunohistochemically, epithelium shows positive expressions of cytokeratins (CK), especially CK5, CK14, and CK19, and mesenchymal tumor cells show positive expression of nestin.
In addition, these proliferations demonstrate an immunohistochemical profile similar to PTC, with strong staining with HBME-1, galectin-3, CK19, and cyclin D1, supporting the concept of a premalignant lesion.
According to Sahoo et al (N=35, in New York), 93% of follicular variants of PTC and all cases of conventional PTC showed diffuse positivity for CK19.
RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathological correlation.
The mRNA level of CK19 was detected using quantitative real-time reverse transcription-polymerase chain reaction (PCR) in all patients, along with a control group of fifty healthy individuals.
The tumour was strongly positive for CK7 and CK19 but focally positive for CK20.
El marcador CK19 en el diagnostico de CPT sigue siendo controvertido, ya que tambien se expresa focalmente en el epitelio normal de la tiroides, la tiroiditis de Hashimoto y los adenomas foliculares.
Immunohistochemical examination of the specimen was positive for cytokeratin (CK)18, CK19, CK5/6 and CD5 and CD117, and negative for CK7, TTF1, CD56 and CD20 markers (Figure 4).
In a case series of four tumors, the authors reported intense and diffuse positivity for CK7, variable expression of epithelial membrane antigen (EMA), vimentin, S100, Ulex europaeus antigen, high-molecular weight CK, CK 8, CK 18 and CK19, and diffuse negativity for carcinoembryonic antigen (CEA), CD15, CD34, desmin, actin, CK10, CK20 and HMB45 [15].
Tumour cells demonstrated immunopositivity for pancytokeratin, vimentin, CD10, CK19 and AMACR (Fig.
CTC expressing EpCAM and/or CK19 were detected in MBC patients using the CellSearch and the EPISPOT assays (Fig.
Variants also presented differences in immunoexpression of CK8-18 and CK19 in podocytes of glomerular lesions [42].